Acceder

Publicaciones - FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA

Cargando...
Ortiz-Fernandez P, Iniesta-Navalon C, Urbieta-Sanz E, Gascon-Canovas JJ. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab". Clin Rheumatol. 2025 Jan 18. doi: 10.1007/s10067-025-07307-0. Online ahead of print. PubMed PMID: 39826047.
AÑO: 2025; IF: 2.9
39826047
Serrano Diaz L, Iniesta Navalon C, Gomez Espin R, Nicolas De Prado I, Bernal Morell E, Rentero Redondo L. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study. Gastroenterol Hepatol. 2024 Jun-Jul;47(6):553-561. doi: 10.1016/j.gastrohep.2023.08.004. Epub 2023 Aug 18. English, Spanish. PubMed PMID: 37597745.
AÑO: 2024; IF: 2.2
37597745
Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Anez-Castano R, Urbieta-Sanz E. Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients. Gastroenterol Hepatol. 2024 Oct 21:S0210-5705(24)00284-X. doi: 10.1016/j.gastrohep.2024.502277. Online ahead of print. English, Spanish. PubMed PMID: 39442691.
AÑO: 2024; IF: 2.2
39442691
Anez-Castano R, Iniesta-Navalon C, Almanchel-Rivadeneyra M, Garcia-Villalba E, Oliver-Galera E, Rentero-Redondo L. Therapeutic drug monitoring of inhaled tobramycin in a patient with chronic kidney disease. Eur J Hosp Pharm. 2024 Dec 30:ejhpharm-2023-004075. doi: 10.1136/ejhpharm-2023-004075. Online ahead of print. PubMed PMID: 39181698.
AÑO: 2024; IF: 1.6
39181698
Iniesta Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2024 Dec 4. doi: 10.17235/reed.2024.10521/2024. Online ahead of print. PubMed PMID: 39629805.
AÑO: 2024; IF: 2.7
39629805
Siguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA